New pages

Jump to navigation Jump to search
New pages
Hide registered users | Show bots | Show redirects

10 June 2026

7 June 2026

  • 21:4221:42, 7 June 2026 Taletrectinib (hist | edit) [32,551 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). |adverseReactions=diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue (>20%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</...")

6 June 2026

  • 22:1522:15, 6 June 2026 GC rich repressor elements (hist | edit) [757 bytes] Marshallsumter (talk | contribs) (Created page with "==GC rich repressor element== GC rich repressor element Down regulation of smooth muscle myosin heavy chain (SM MHC) expression in cultured smooth muscle cells is associated with progressive methylation of a GC rich repressor element (GCGGGA) within the SM MHC promoter.[1] ==References== 1. Julian M Rozenberg, Daniel B Tesfu, Srilaxmi Musunuri, Joan M Taylor & Christopher P Mack (December 2014). DNA methylation...")
  • 19:4019:40, 6 June 2026 Α-Palindromic binding proteins (hist | edit) [1,001 bytes] Marshallsumter (talk | contribs) (Created page with "α-Palindromic binding proteins The palindromic sequence here designated Order 377 (r) TGCGCATGCGCA (c) ACGCGTACGCGT (1) (i) TGCGCATGCGCA (ci) ACGCGTACGCGT (1) also called the α-palindromic binding protein (α-PAL) that binds the nuclear respiratory factor 1 (NRF-1)[1] does not occur on either side of A1BG nor any other IDC. Number 377 Order 377 alpha palindromic binding protein (r) TGCGCATGCGCA = (i)...")

5 June 2026

  • 12:5312:53, 5 June 2026 Clesrovimab-cfor (hist | edit) [21,291 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein-directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. |adverseReactions=injection-site erythema (3.8%), injection-site swelling (2.7%) and rash (2.3%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</...")

3 June 2026

  • 13:1313:13, 3 June 2026 Acoltremon (hist | edit) [10,394 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=TRPM8 thermoreceptor agonist |indicationType=treatment |indication=the signs and symptoms of dry eye disease. |adverseReactions=instillation site pain (50%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult=====FDA-labeled Indications==== * TRYPTYR is indicated for the...")

2 June 2026

  • 14:2714:27, 2 June 2026 Telisotuzumab vedotin-tllv (hist | edit) [28,383 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=a c-Met-directed antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. |adverseReactions=were perip...")

25 May 2026

  • 13:3713:37, 25 May 2026 Avutometinib potassium and Defactinib hydrochloride (hist | edit) [35,103 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Avutometinib and Defactinib |aOrAn=a |drugClass=combination of avutometinib and defactinib, each kinase inhibitors, |indicationType=treatment |indication=adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. |adverseReactions=laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase...")
  • 11:5511:55, 25 May 2026 Nipocalimab-aahu (hist | edit) [30,203 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Nipocalimab |aOrAn=a |drugClass=neonatal Fc receptor blocker |indicationType=treatment |indication=generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReactions=respiratory tract infections, peripheral edema, and muscle spasms ( in patients with gMG treate...")

24 May 2026

  • 02:3402:34, 24 May 2026 Penpulimab (hist | edit) [42,564 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Penpulimab |aOrAn=a |drugClass=programmed death receptor-1 (PD-1)-blocking antibody |indicationType=treatment |indication=* In combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). * As a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progres...")

23 May 2026

  • 22:1122:11, 23 May 2026 Atrasentan (hist | edit) [23,500 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Atrasentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. |hasBlackBoxWarning=Yes |adverseReactions=peripheral edema and anemia (incidence >5%). |blackBoxWarningTitle='''<span style="color:#FF0000;"> EMBRYO-FE...")

22 May 2026

  • 01:5301:53, 22 May 2026 Fitusiran (hist | edit) [36,754 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=antithrombin-directed small interfering ribonucleic acid |indicationType=prophylaxis |indication=to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. |adverseReactions=viral infection, nasopharyngitis, and bacterial infection. |blackBoxWarningTitle='''<span style="co...")

21 May 2026

  • 14:0614:06, 21 May 2026 Gepotidacin (hist | edit) [42,400 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=triazaacenaphthylene bacterial type II topoisomerase inhibitor |indicationType=treatment |indication=of the following infections caused by susceptible microorganisms: * Uncomplicated urinary tract infections (uUTI) in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg). * Uncomplicated Urogenital Gonorrhea: The recommended dosage of BLUJEPA is 3,000 mg (four 750 mg tablets)...") originally created as "Gepoticadin"

20 May 2026

18 May 2026

Retrieved from "https://www.wikidoc.org/index.php/Special:NewPages"